Protalix BioTherapeutics
PLX
PLX
65 hedge funds and large institutions have $18M invested in Protalix BioTherapeutics in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 16 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
7% more funds holding
Funds holding: 61 → 65 (+4)
1.04% more ownership
Funds ownership: 12.81% → 13.84% (+1%)
Holders
65
Holding in Top 10
–
Calls
$984K
Puts
$150K
Top Buyers
| 1 | +$534K | |
| 2 | +$502K | |
| 3 | +$184K | |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$156K |
| 5 |
Barclays
London,
United Kingdom
|
+$141K |
Top Sellers
| 1 | -$229K | |
| 2 | -$172K | |
| 3 | -$116K | |
| 4 |
SOW
State of Wyoming
Cheyenne,
Wyoming
|
-$68.5K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$52.6K |